A B S T R A C T Analogues of cobalamin (
with native Cbl when it is present in plasma in unbound form.
All of the Cbl analogues were bound by the granulocyte R-type Cbl-binding protein with high affinity and all ofthe R-type protein-[57Co]Cbl analogue complexes were cleared rapidly from plasma exclusively by hepatocytes as occurs with R-type protein-[58Co]Cbl. Some Cbl analogues were released back into the plasma and were disseminated among a variety of tissues via transcobalamin II as occurs with native Cbl. Other Cbl analogues were retained in the liver and eventually excreted in the feces and urine without accumulating in other tissues.
These studies indicate that intrinsic factor and the ileum prevent certain Cbl analogues from entering the body and that the granulocyte R-type protein and hepatocytes prevent the dissemination of certain Cbl analogues that may gain entry such as during infections with Cbl analogue-producing bacteria. The fact that transcobalamin II binds and transports a large number of Cbl analogues indicates that these protective mechanisms can be circumvented and supports the feasibility of using Cbl analogues as antimetabolites in vivo.
quire 5'-deoxyadenosyl-Cbl and methyl-Cbl as coenzymes for methylmalonyl-CoA mutase and methionine synthetase, respectively (2) . Consequently, man and other animals have developed intricate mechanisms for the gastrointestinal absorption and plasma transport of this trace substance (3) (4) (5) .
Gastric intrinsic factor (IF) binds Cbl and facilitates its uptake by ileal mucosal cells which contain receptors that specifically bind the IF-Cbl complex but not apo-IF or free Cbl (3, 6) . Cbl then enters the ileal mucosal cell and is subsequently released into the portal plasma although the mechanisms involved and the fate of IF are unknown (3) (4) (5) .
Plasma transcobalamin II (TC II) binds Cbl and facilitates its uptake by a variety of tissues which contain receptors that specifically bind the TC II-Cbl complex and apo-TC II but not free Cbl (7, 8) . The TC II-Cbl complex appears to be taken up by pinocytosis, and after fusion of the pinocytotic vesicles with lysosomes the TC II moiety is degraded (7, 9, 10) . Some of the liberated Cbl is released from cells (7, 11) whereas other molecules are retained and become bound to the two mammalian Cbl-dependent enzymes methylmalonyl-CoA mutase and methionine synthetase (12, 13) .
Granulocyte R-type Cbl-binding protein (GRP) binds Cbl and facilitates its uptake exclusively by hepatocytes (14) which contain receptors with specificity for a variety of asialoglycoproteins (15) . These receptors bind GRP-Cbl and apo-GRP but not free Cbl (14) . Hepatic uptake of the GRP-Cbl complex also appears to involve pinocytosis (15) . of the GRP-Cbl molecules are excreted intact into the bile by an undefined mechanism whereas the protein moiety of the remaining 80-90% of the molecules is degraded in lysosomes (14, 15) . Most of the liberated Cbl is released back into plasma where it is present bound to TC II although 10-20% of the liberated Cbl appears to be retained by hepatocytes and is present bound to methylmalonyl-CoA mutase and methionine synthetase (12) .
The possible gastrointestinal absorption and plasma transport of Cbl analogues is of interest because a variety of Cbl analogues are synthesized and utilized by bacteria (2, 16) . The fact that some naturally occurring analogues are inactive (17) (23) in which CN-Cbl was incubated at 65°C for 6 min in concentrated HC1. The sample was diluted with 10 vol of H20, and the chloride was removed by application to a 2.0 x 30-cm column of Dowex AG 1 x 8 acetate, equilibrated in H20 at 4°C. After elution with 0.05 M acetic acid, the sample was lyophilized, dissolved in H20, and applied to a 0.7 x 4.0-cm column of phosphocellulose equilibrated with 0.01 M acetic acid. After washing with four-column volumes of0.01 N acetic acid, the sample was eluted with 1 N NaCl. The salt was removed by phenol extraction (24) KA CN-analogue
2 These values may in part represent relative rates of association ofCbl analogue and native Cbl since a true equilibrium may not have been achieved during the relatively short time periods utilized for these determinations. This seems unlikely, however, since differences were not observed when incubations were extended to 60 min. Incubations of several days' duration could not be performed due to instability of the protein preparations at 37°C under these conditions. In any event, the values obtained appear to be the important ones from a physiologic standpoint.
The charcoal adsorption technique was also used to measure the association constant of CN-Cbl for CblBP. The basic technique described above was modified in the following manner: (a) high specific activity CN-[57Co]Cbl, (200 ,uCi/,ug) was used in amounts ranging from 5 to 100 fmol; (b) the amount of CblBP was reduced to 12.5 fmol of Cblbinding ability; (c) the amount of bovine serum albumin was reduced to 25 ,ug/ml; and (d) the incubation time at 37°C was increased to 2 h. Double reciprocal plots of 1/CN-[57Co]Cbl free vs. I/CN-[57Co]Cbl bound were prepared as described previously (6) .
Animal studies. Male New Zealand white rabbits were prepared, injected, and their organs assayed for radioactivity as previously described (7, 14) . , were administered simultaneously the ratios via each of the transport systems obtained in all organs and tissues averaged 1.0 and were never outside the range of 0.8-1.2. Data are presented in general only for heart, lung, kidney, liver, and bowel but Cbl and Cbl analogues were also found diffusely distributed in essentially all other organs and tissues. The total body content of radioactive Cbl and Cbl analogues plus that excreted in the urine and feces always agreed well with the content of administered radioactivity.
RESULTS
Synthesis of Cbl and Cbl analogues. The structure of CN-Cbl and the presumed partial structures of the 14 Cbl analogues are shown in Fig. 1 . All of the analogues were synthesized by standard techniques as described under Methods. The structures of the Cbl analogues have been determined previously using a variety of techniques (16) including the ultimate method of X-ray crystallography in some cases. All of the analogues gave single red spots on paper chromatography and their Rf values differed from that of CN-Cbl as shown in Table I . Single radioactive peaks were obtained with each ofthe 57Co and 58Co analogues. The Rf value for each radioactive analogue was the same as for the corresponding unlabeled analogue.
Affinity of Cbl and Cbl analogues for CblBP. The association constant for CN-Cbl and each of the rabbit and human CblBP was determined as described under Methods. The order of the association constants for CN-Cbl for rabbit CblBP was GRP > TC II > IF with values of 8.0, 2.6, and 0.5 pM-1, respectively. The order for human CblBP was GRP > IF > TC II with values of 7.5, 1.9, and 0.5 pM-1, respectively. Table I . They indicate that rabbit and human IF are the most selective CblBP and have relatively low affinities (i.e. KA analogue/KA Cbl < 0.01) for analogues missing the b or e or b, d, e amino groups, as well as for those in which the BZA portion of the nucleotide moiety has been replaced by a purine, or can not coordinate with the cobalt moiety. Rabbit and human TC II are less selective and have low affinities only for the analogues missing the b or b, d, e amino groups and those in which the nucleotide moiety can not coordinate with the cobalt moiety. Rabbit and human GRP are the least selective CblBP and bind all ofthe analogues studied with relatively high affinity. In contrast to these differences among classes of CblBP differences among corresponding rabbit and human CblBP are much less striking.
Absorption and ileal retentiotl of CN-Cbl and CNCbl analogues. Previous studies (3) (4) (5) (6) have shown that IF-Cbl binds to ileal cell surface receptors. Cbl then enters the ileal cell and, after a delay of several hours, is released into the portal blood. Cbl were administered orally to rabbits at the same time. The absorption ofthe analogue was delayed and reduced relative to native Cbl despite the fact that this analogue and native Cbl were bound to rabbit IF with the same affinity. After 24 h, the analogue was present in excess of native Cbl in the ileum which indicates that entry into the ileal cell after binding to ileal receptors, or release into the portal blood from the ileal cell, was delayed. Table I . Fig. 4 . The 1-h data indicate that this analogue was cleared from plasma with a rate and tissue distribution that were very similar to those of native Cbl. The fact that the plasma and tissue levels of this analogue were slightly less than those of native Cbl at 1 h, and the fact that urinary excretion was slightly greater, may be due to the fact that the These studies indicate that binding to TC II with high affinity is a necessary and sufficient condition for the cellular uptake of Cbl analogues. This is not surprising since previous studies (7, 8, 10) after injection. Analyses of small intestinal contents, and in some cases bile obtained by bile duct cannulation, indicated that the early (first 60 min) biliary excretion, which ranged from 10 to 25% of the administered radioactivity in individual rabbits, was the same as CN-Cbl for each of the Cbl analogues. The same appeared to be true for late (60-240 min) biliary excretion which represented 5-10% of the administered radioactivity. An exception was [5,6-Cl2BZA]CN-Cba which had a late biliary excretion that was three-to fivefold greater than that of CN-Cbl. This difference was observed repeatedly. Analyses of bile employing gel filtration (14) revealed that similar amounts of [5,6-Cl2BZA]Cba and Cbl were present bound to GRP in early bile fractions and that all of the excess [5, Cba in the late bile fractions was present either as free [5, Cba or, to a lesser extent, bound to TC II.
In many cases the rate at which Cbl analogues were excreted into the plasma after their initial hepatic uptakes were much slower than that of native Cbl. This is illustrated in Fig. 5 at various times after their simultaneous intravenous injection into rabbits. At 0.5 h after injection most of the analogue and Cbl were present in the liver except for the amounts that enter the jejunum via the bile. By 2 h after injection more than half of the native [58Co]Cbl had left the liver and had a wide tissue distribution similar to that observed when Cbl is injected bound to TC IL. In contrast, [57Co]Cbi was retained by the liver and >150 h were required before the hepatic level of this analogue decreased to one-half of its initial level. Experiments of this kind were performed with each Cbl analogue and utilized to estimate the rate at which they were released into plasma from the liver. The values obtained are presented in Table IV and indicate that alterations in the nucleotide moiety of Cbl effect the greatest reductions in its rate of release into plasma from the liver. Analyses of hepatic homogenates by gel filtration (12) suggested that all of the GRP-Cbl analogues were converted to free Cbl analogue by 45 min after injection and that most of each Cbl analogue remained in unbound form at later time periods. These observations indicate that hepatic retention of Cbl analogues is not due to an inability to liberate Cbl analogues from GRP or to excessive binding of Cbl analogues by intracellular Cbl-dependent enzymes although they do not rule out the possibility that they are bound by a different intracellular CblBP that is denatured, or releases Cbl, during the preparation of tissue for gel filtration.
A comparison between Tables IV and I shows that the mechanism that effects the hepatic release of Cbl into plasma has a structural specificity that is distinct from those of binding to IF, TC II, and GRP. Preliminary studies also indicate that this mechanism is saturable with a maximal release rate of 2,000 ng of Cbl per h, and that Cbl analogues compete with native Cbl for release. 3 The studies in this section indicate that binding to GRP with high affinity is a necessary and sufficient condition for the hepatocyte uptake of Cbl analogues. This is not unexpected since previous studies (14) have shown that both holo-GRP and apo-GRP bind to the same cell surface receptors and enter hepatocytes intact, thus indicating that the structure of the Cbl molecule is not important in this process. The studies presented here also indicate that the structure of the Cbl molecule is unimportant in the undefined mechanism by which GRP-Cbl is excreted into the bile in intact form. The structure of the Cbl molecule is important, however, in the processes involving the plasma and late biliary excretion of Cbl by hepatocytes although the structural specificities of these processes differ from each other and from those of binding to IF, TC II, and GRP.
Comparison Fig. 6 and show that the long-term distribution of the analogue injected bound to GRP remains confined to the liver although the same analogue bound to TC II remains widely distributed. Despite this difference it is interesting that both forms of the analogue are excreted in the urine and feces in similar amounts and at similar rates. It is unclear how this analogue moves from the liver to the urine without being taken up by other tissues especially since rabbit plasma contains 10-20 pmol of unsaturated TC II Cbl-binding ability per ml (7). 3 (36) (37) (38) that suggested that IF is the most selective CblBP and that this selectivity prevents the absorption of many Cbl analogues. We have also shown that a separate ileal mechanism exists which leads to the ileal retention of Cbl analogues and prevents their entry into the portal blood.
The studies presented here also suggest that animals possess additional mechanisms that function to prevent the tissue dissemination of Cbl analogues that do gain access to the body, and that these mechanisms are also effective with respect to the most common naturally occurring Cbl analogues. We have shown that GRP binds a wide variety of Cbl analogues with high affinity. This lack of selectivity appears to enhance the antibacterial function of GRP since this protein can bind Cbl and Cbl analogues and make them unavailable for certain bacteria that require them for growth. GRP has the following characteristics that favor it over TC II in terms of competing for binding of Cbl analogues in vivo: (a) GRP has a higher affinity for Cbl and Cbl analogues than TC II; (b) GRP retains its high affinity over a pH range of [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] whereas that of TC II decreases markedly below pH 5 (39) and is thus relatively ineffective in areas of necrosis or infection; and (c) GRP is located in the specific granules of granulocytes (40) from which it is released into phagosomes and also extracellularly (41, 42) . The enhanced ability of GRP to bind Cbl analogues enables them to be transported exclusively to hepatocytes rather than to other tissues which may be more susceptable to their toxic effects. Our studies demonstrate that delivery to hepatocytes prevents the dissemination of many Cbl analogues since at least one analogue is preferentially excreted in the bile and others are retained intracellularly. The latter are eventually excreted in the urine and feces although the mechanism by which they reach the urine is not known. The fact that they do so without being bound and disseminated by TC (43) .
The studies presented here also support the feasability of utilizing Cbl analogues as antimetabolites in vivo since our data indicate that TC II is capable of binding a large number of Cbl analogues and transporting them to a variety of tissues. This information would be useful in evaluating Cbl analogues for toxicity and in studies designed to correlate such toxicity with the inhibition of individual Cbl-dependent enzymes. Studies of this kind could lead to a better understanding of the biochemical basis of the megaloblastic anemia and neurologic defects associated with Cbl deficiency, as well as to the development of a new class of chemotherapeutic agents for malignancies. Investigation of the latter possibility appears particularly interesting since several recent studies (44, 45) indicate that a number of malignant cell lines differ from normal cells in terms of their activities of, and/or their dependence on, the Cbl-dependent enzyme methionine synthetase which catalyzes the conversion of N5-methyltetrahydrofolate and homocysteine to tetrahydrofolate and methionine.
